Core Insights - Vivos Inc. is advancing its RadioGel technology, a Precision Radionuclide Therapy (PRnT), and is working towards securing FDA Investigational Device Exemption (IDE) approval for human clinical trials [1][6] Company Efforts - The company has engaged extensively with the FDA, addressing feedback from over 40 reviewers and finalizing key technical parameters to demonstrate the precision delivery of RadioGel [3] - Vivos has hired a top regulatory expert in brachytherapy to enhance its IDE submission, leveraging the expert's experience with successful IDE approvals for similar devices [4] - The company plans to submit the IDE by the end of Q1 or in April, indicating a strong commitment to advancing RadioGel towards human clinical trials [6] Submission Enhancements - The IDE submission will include fully addressing FDA concerns, incorporating new clinical human data, and reformatting pre-clinical data to better meet FDA expectations [8] - The submission will leverage extensive veterinary clinical data from IsoPet, showcasing over 100 safely administered therapies with no serious adverse events, to strengthen the evidence for safety and efficacy [8] - Specialized equine ocular applications will be highlighted, including successful treatments of ocular squamous cell carcinoma in horses, demonstrating the therapy's precision and minimal invasiveness [8]

Core Insights - Vivos Inc. is advancing its human clinical trial for RadioGel Precision Radionuclide Therapy in India, which is designated as a Breakthrough Device by the FDA for treating solid tumors [1][10] Clinical Progress - The trial has successfully treated ten patients, confirming a strong safety profile and early evidence of efficacy, building on initial results that confirmed safety in the first five patients [2][3] - All patients have met the primary safety endpoint, with PET imaging showing precise retention of Yttrium-90 isotope at the injection site and no adverse events reported [3] - RadioGel has successfully treated tumors in high-risk anatomical regions without damaging adjacent critical tissues, demonstrating a high Therapeutic Ratio [4] Technical Innovations - The clinical team has implemented new technical refinements, including deep-needle injection techniques and precision image guidance, enhancing dose control and organ protection [6] - Ongoing discussions with Mayo Clinic investigators are aimed at preparing for a parallel clinical study in the U.S. [6] Expansion Plans - The study in India is approved to treat 30 patients, with a request being prepared to increase this to 50 patients to evaluate RadioGel in a broader range of tumor types [7] - Vivos is establishing a permanent operational presence in India, including plans for a corporate office and a regional manufacturing facility for yttrium phosphate microparticles [8] Market Opportunity - The cancer treatment market in India was valued at approximately USD 4.21 billion in 2023 and is projected to reach USD 5.89 billion by 2030, presenting a significant opportunity for innovative therapies like RadioGel [12] - Establishing a presence in India allows Vivos to diversify revenue streams and enhance global recognition of RadioGel as a relevant oncology solution [12] Regulatory Strategy - Vivos is sharing preliminary trial data with the FDA to support an Investigational Device Exemption (IDE) submission within the next 90 days [10] - The company is pursuing a multi-track global strategy to ensure momentum in regulatory progress, particularly in regions with streamlined pathways for innovative cancer therapies [10][11]